Table 1. Clinicopathological correlates of predominant cell morphology in glioblastoma.

	Age (years)	Survival (months)	IDH1 mutation	MGMT methylation
All glioblastoma	60.0 y	5.7 m	8/274 (2.9%)	93/247 (37.7%)
Fibrillary	60.7 y	4.9 m	2/147 (1.4%)	38/131 (29.0%)
Gemistocytic	58.7 y	4.1 m	0/22 (0%)	2/15 (13.3%)
Giant cell	66.1 y	5.3 m	1/11 (9.1%)	7/11 (63.6%)
Small cell	60.9 y	7.3 m	2/19 (10.5%)	9/18 (50.0%)
Oligodendroglial	55.2 y	8.9 m	3/59 (5.1%)	32/59 (54.2%)
Sarcomatous	65.1 y	7.5 m	0/16 (0%)	5/14 (35.7%)